SlideShare una empresa de Scribd logo
1 de 39
Descargar para leer sin conexión
!"#$%"&#'$()*$#)"+,-*$%.,/"0.,")1$"2$(3.#($")."!&45"
                         "
   6.,$"7-89$"0.,")1$"6.#$:"%;)1;#"-"+,-*$%.,/".0"
                51-,$<"2$(3.#(;=;8;):"
Resources available for HIV
in low and middle income countries, 1986-2010
We have done a
  lot…
!  >#3,$?$<$#)$<"(?-8$"93".0"@&7"
   3,$'$#A.#B"),$-)*$#)B"?-,$"-#<"
   (933.,)"
!  4$?8;#$";#",-)$".0"#$%"@&7"
   ;#0$?A.#(";#"*-#:"?.9#),;$("
!  6.,$")1-#"CDC"*;88;.#"3$.38$".#"
   !2E"
!  6;88;.#(".0".,31-#(",$?$;';#F"=-(;?"
   $<9?-A.#B"1$-8)1B"(.?;-8"3,.)$?A.#"
But we can do
better
5?-8$"93")."<-)$"F9;<$<"=:"-"
   G?.**.<;):"-33,.-?1H"
"
!  >#(:()$*-A?"3,;.,;A(-A.#"-#<"
   ;#'$()*$#)"%;)1"8;*;)$<"=-(;(";#"
   ?.9#),:"$3;<$*;.8.F:"-#<"?.#)$I)"
!  2$(.9,?$("(3,$-<")1;#8:"-?,.(("
   *-#:"3-,-88$8";#)$,'$#A.#("
!  +.?9(".#"<;(?,$)$";#)$,'$#A.#("
   ,-)1$,")1-#".'$,-88",$(98)("8$-<;#F"
   )."-"0,-F*$#)$<",$(3.#($"
New Investment Framework

  CRITICAL                       BASIC PROGRAMME ACTIVITIES                                    OBJECTIVES
  ENABLERS

  Social enablers                  Key                    Children &
                                   populations            mothers
  •  Political commitment &
                                                                                                Stopping new
     advocacy
  •  Laws, policies &                                                                             infections
     practices
  •  Community mobilization      Behaviour
  •  Stigma reduction            change                  Condoms
  •  Mass media
  •  Local responses, to
     change risk
     environment

  Programme enablers                                                                               Keeping
  •  Community-centered                                                                          people alive
     design & delivery
  •  Programme
     communication                  Care &                 Male
  •  Management & incentives        treatment              circumcision
  •  Production & distribution
  •  Research & innovation

 SYNERGIES WITH DEVELOPMENT SECTORS
 Social protection; Education; Legal Reform; Gender equality; Poverty reduction; Gender-based violence;
 Health systems (incl. treatment of STIs, blood safety); Community systems; Employer practices.
Three investment scenarios
Impact on the epidemic
                  %"

                  %!

                  $"
>54"JK;88;.#(L"




                  $!
                                                                                         K9(;#$(("-("9(9-8"
                  #"                                                                         M"NDO"




                                                                                                      R$%"@&7"&#0$?A.#("
                                                                                             M"NDP"




                                                                                                         J*;88;.#(L"
                  #!
                                                                                             M"QDO"
                   "                                                                         M"QDP"
                                                                                             M"PDO"
                   !                                                                         M"P"
                       $!##   $!#$   $!#%   $!#&   $!#"   $!#'   $!#(   $!#)   $!#*   $!$!
Three investment scenarios
Impact on the epidemic
                  %"

                  %!

                  $"
>54"JK;88;.#(L"




                  $!                                                                     &#'$()*$#)"0,-*$%.,/"
                                                                                         K9(;#$(("-("9(9-8"
                  #"                                                                         M"NDO"




                                                                                                      R$%"@&7"&#0$?A.#("
                                                                                             M"NDP"




                                                                                                         J*;88;.#(L"
                  #!
                                                                                             M"QDO"
                   "                                                                         M"QDP"
                                                                                             M"PDO"
                   !                                                                         M"P"
                       $!##   $!#$   $!#%   $!#&   $!#"   $!#'   $!#(   $!#)   $!#*   $!$!
Three investment scenarios
Impact on the epidemic
                  %"
                                                                                         2-3;<"(?-8$"93"
                                                                                         3,$';.9("3,.S$?A.#("
                  %!

                  $"
>54"JK;88;.#(L"




                  $!                                                                     &#'$()*$#)"0,-*$%.,/"
                                                                                         K9(;#$(("-("9(9-8"
                  #"                                                                         M"NDO"




                                                                                                      R$%"@&7"&#0$?A.#("
                                                                                             M"NDP"




                                                                                                         J*;88;.#(L"
                  #!
                                                                                             M"QDO"
                   "                                                                         M"QDP"
                                                                                             M"PDO"
                   !                                                                         M"P"
                       $!##   $!#$   $!#%   $!#&   $!#"   $!#'   $!#(   $!#)   $!#*   $!$!
E1$"#$%";#'$()*$#)"0,-*$%.,/"
+.?9(".#"%1-)"*-/$("-"<;T$,$#?$"
                >54"JK;88;.#(L"
   $"



   $!


                                                                                 5:#$,F;$("
   #"

                                                                              V,;A?-8"W#-=8$,("
   #!



   "                                                                          K-(;?"U,.F,-**$"
                                                                                  !?A';A$("

   !
        $!##   $!#$   $!#%   $!#&   $!#"   $!#'   $!#(   $!#)   $!#*   $!$!
ART coverage in 2015 by CD4 count

               #!!"
                                   CD4 350
               +!"

               *!"
                      15 million
               )!"

               (!"
    V.'$,-F$




               '!"

               &!"

               %!"
                        T4P                              13.1 million (health)
               $!"

               #!"

                !"
                      ,'!!    %'!-&++    $'!-%&+        $!!-$&+     #!!-#++   '!-++   .'!

                                                   V4X"V.9#)"J?$88(Y*8L
Returns on investment of new
investment framework (2011-2020)


                                 Outcomes
  Total infections averted    More than 12 million

  Infant infections averted            1.9 million

  Deaths averted                       7.4 million

  Life years gained                   29.4 million
New investment framework: the tipping point




                           R$%8:"$8;F;=8$"0.,"),$-)*$#)"

                           R$%8:";#0$?)$<"
New infections, behaviour change and treatment
coverage in Botswana


                         Behaviour change




    New infections and
    treatment coverage
Cost and economic returns
2011 to 2020

                                Cost/Returns
  Total additional investment
                                    US$46.5 Billion
  (over 10 years)
  Future treatment need
                                     US$40 Billion
  averted
                                           US$1,060
  Life years gained
                                per life year gained
Investment framework projections for new HIV
infections

   Optimized investment will lead to rapid declines in new HIV infections in many countries
V.**9#;):"*.=;8;Z-A.#"-((9*3A.#(";#")1$"
;#'$()*$#)"0,-*$%.,/""
V.()"$#'$8.3$["?.**9#;):"*.=;8;(-A.#"?.*3.#$#)".0")1$"
    ?,;A?-8"$#-=8$,("""
"
////$!##//0!1%23/       //$!#'/0!1(/23/
                                      /    /$!$!/0#1!/23//
/
!((9*3A.#(["
•  43567897:/5;<<=3>?@/58A85>?@//
•  >3567897:/5;<<=3>?@/976B>57/:7C>B76@///
•  377:/D;6/67<=3768E;3/;D/5;<<=3>?@/83:/C8@/F;6G769//
•  377:/D;6/?68>3>3HI/H=>:8357I/9=A76B>9>;3/
•  A86E5>A8E;3/;D/A7;AC7/C>B>3H/F>?J/K4L/
V.**9#;):"*.=;8;Z-A.#["*-/$("(?-8$"93"3.((;=8$""

 •  R9*=$,".0"3$.38$")$()$<")1,.9F1"?.**9#;):"
     *.=;8;Z-A.#""
    /$!#!M/&(/<>CC>;3/NLOPQ/// /$!#'M/#!+/<>CC>;3//
 /


 •  5$,';?$"<$8;'$,:"?.()("J),$-)*$#)L""
    /$!#!M/0#)+/A76/@786///
    /$!$!M/0#$'/A76/@786/N0#)/>3/C;F/>35;<7/5;=3?6>79Q//
 /


 •  4,;';#F"?.()("<.%#["0$%$,".9)3-A$#)"';(;)(B"
    ?.**9#;):"(933.,)"($,';?$"*.<-8;A$("
 •  K$$,"@$-8)1"]9)?.*$("
V.**9#;):"*.=;8;Z-A.#[""
;#?,$-($("$T$?A'$#$(("
•  O;<<=3>?@/<;2>C>98E;3/>3567897:/K4L/?79E3H/68?79/D;=6-
   D;C:/>3/P83R83>8I/S><282F7I/T;=?J/UD6>58/83:/PJ8>C83:1/
//
•  O;39>9?73?/5;3:;</=97/>3/A89?/#$/<;3?J9/&/E<79/J>HJ76/>3/
   5;<<=3>E79/F>?J/H;;:/5;<<=3>?@/73H8H7<73?/NV73@8Q//
//
•  K@A;?J7E58C/5>65=<5>9>;3/<;:7C/VF8S=C=-W8?8C/M//
    –  5;67/>3?76B73E;3M//$&!I!!!/>3D75E;39/8B76?7:/;B76/?73/@7869/
    –  F>?J/7382C769M/&$!I!!!/>3D75E;39/8B76?7:I/F>?J/<;:79?/
       <86H>38C/>3567897/>3/5;9?9/
/
Investement framework allocation in 2015
E-#Z-#;-["-##9-8"#$%"@&7";#0$?A.#(B"NPQQMNPNP"


 #(!!!!/

 #&!!!!/                    K-($8;#$"J=9(;#$(("-("9(9-8L"

 #$!!!!/

 #!!!!!/

  *!!!!/

  (!!!!/
                                       &#'$()*$#)"+,-*$%.,/"
  &!!!!/

  $!!!!/

      !/
           $!##/ $!#$/ $!#%/ $!#&/ $!#'/ $!#(/ $!#)/ $!#*/ $!#+/ $!$!/
E-#Z-#;-["-##9-8"!&45"<$-)1(B"NPQQMNPNP"


 #&!!!!/
                          K-($8;#$"J=9(;#$(("-("9(9-8L"
 #$!!!!/

 #!!!!!/

  *!!!!/

  (!!!!/

  &!!!!/                               &#'$()*$#)"+,-*$%.,/"

  $!!!!/

      !/
           $!##/$!#$/$!#%/$!#&/$!#'/$!#(/$!#)/$!#*/$!#+/$!$!/
Investment framwork tanzania_cs-powerpoint
Investment framwork tanzania_cs-powerpoint
Resources available for HIV
in low and middle income countries, globally, 2002-2010
Percentage of care and treatment
expenditure from international sources
Few donors meet the development assistance targets


                 Norway                                            1.10%
            Luxembourg                                             1.09%
                 Sweden                                        0.97%
                Denmark                                      0.90%
             Netherlands                                  0.81%
                 Belgium                          0.64%
         United Kingdom                        0.56%
                  Finland                     0.55%
                  Ireland                    0.53%
                  France                    0.50%
                    Spain                0.43%
             Switzerland                0.41%             Net development assistance
               Germany                 0.38%
                 Canada              0.33%                in 2001 as % of gross
                  Austria
                Australia
                                    0.32%
                                    0.32%
                                                          national income
                Portugal           0.29%
           New Zealand            0.26%
           United States        0.21%
                   Japan        0.20%
                  Greece       0.17%
                     Italy    0.15%
                   Korea     0.12%
                        0%      0.3%    0.5% 0.7%              1% 1.2%
Measuring national commitment to AIDS:
the Domestic Investment Priority Index




SOURCE: UNAIDS expenditure data; WHO data on the burden disease; and economic data from the International Monetary Fund World Economic Outlook database
Economic growth in Africa, 1970–2010
Third-fastest growing region in the World
Three options for increasing domestic public HIV
investment in Africa
Projected resource needs (in USD billion)
Assumed increases of domestic contributions by BRICS and others
within ability to pay (economic growth and towards Abudja targets)




                                                                                   Development Assistance
                                                                             8.0
                                                                10.7   9.4
                                                  12.7   11.8
                                  13.6   13.5
                           13.0
                    11.9
             11.3




                                                                                   Domestic financing
       9.7
                                          LI
                                         LMI
                                         UMI
                                         XY4OT/
T;<7/Z=79E;39
                         /
•  [J8?/867/?J7/9?68?7H>5/;A73>3H9/D;6/8/37F/
   :>8C;H=7/86;=3:/75>735@]/
•  U67/?J767/;2B>;=9/<>9-<8?5J79/27?F773/?J7/
   7A>:7<>5/83:/?J7/679A;397]/
•  [J>5J/867/?J7/D85?;69/?J8?/<8G7/>?/:>5=C?/?;/
   958C7/=A/289>5/A6;H68<<7/5;<A;373?9]//
•  K;F/5;=C:/A86?3769/J7CA/>3/8AAC>58E;3/;D/?J7/
   4^/8AA6;85J/
The beginning of the end of
AIDS is in our hands
Investment framwork tanzania_cs-powerpoint
Y785J>3H/A7;AC7/F>?J/976B>579M
                                /
              _`8<AC79/D;6/$!#'/
                                   V.'$,-F$"
                                J3.398-A.#",$-?1$<L
                                                  "
O;3:;<9/N:>95;6:83?/5;=AC79Q/        (!" /
O;3:;<9/NJ>HJ/6>9G/A;AQ/             '!" /
T7`/F;6G/                            (!" /
aTa/A6;H68<<79/                      (!" /
4bc/A6;H68<<79/                      (!" /
                                    6;88;.#"
K4L/?79E3H/                          %$! /
UYP/NOb&/%'!I/P&dQ/               ?;F86:9/#' /
O;9?/A76/A8E73?/A76/@786/
                                    /
              NF7>HJ?7:/8B768H7/>3/cT0Q
                                      /
  "    "       "        "    "NPQP "      "NPQO "     "NPNP"
/
e82/N37F/A8E73?9Q///////     /#*!//// /   /#$+/   /   /)+//
/
e82/N5;3?/A8E73?9Q////////   /#*!/    /   /#$*/   /   /)(//
/
T76B>57/:7C>B76@/      /     /#)(/    /   /#&&/   /   /##$//
/
#9?/e>37/UYL9/ /       /     /#''     /   /#&)/   /   /')//
/
$3:/e>37/UYL9/ /       /     /#()* /      /+*&    /   /$+'//
P79E3H/83:/O;=397C>3H /
      O;B768H7/83:/5;9?/A76/A769;3/
                                   !"#$%&'(%)*+',$%)"-,#'**'.%/,.%$'#$'.
0:1

091

081

071

061

051

041

031

021

01
  1;




                                                 6;
         ;


                ;


                       ;


                              ;


                                     ;


                                            ;




                                                        ;


                                                              ;


                                                                     ;


                                                                           ;


                                                                                 ;


                                                                                       ;


                                                                                             ;


                                                                                                   ;


                                                                                                         ;
                                                      26


                                                            36


                                                                   46


                                                                         56


                                                                               66


                                                                                     76


                                                                                           86


                                                                                                 96


                                                                                                       :6
         12


                14


                       16


                              31


                                     51


                                            86
       1<


              1<


                     1<


                            1<


                                   1<


                                          1<




                                                        !"='(/>'
fTP/O;9?/U99=<AE;39
                           /
V.()".0"6$)1-<.#$[""
•  %%5/D;6/*!<H/>3/4683/?;/0$1!(/D;6/*!<H/>3/
   43:;379>8/

•  U2;=?/cTb/#!!!/A76/A769;3/@786/

•  g;>3H/:;F3/2@/$!"/>3/$!#'/83:/2@/J8CD/>3/
   $!$!/
X7J8B>;6/OJ83H7/d6;H68<<79
                            /
•  e>hC7/7B>:7357/D;6/7i75EB73799/
•  e>hC7/>3D;6<8E;3/;3/5;9?/
•  U9/8/A6;`@M/5;9?/F;6GAC857/A6;H68<9/N2@/$!#'I/
   '!"/5;B768H7/;D/?J7/#&*/<>CC>;3/7<AC;@779/>3/
   ?J7/D;6<8C/975?;6/>3/5;=3?6>79/F>?J/
   H73768C>R7:/7A>:7<>59I/8B768H7/=3>?/5;9?/;D/cT
   0/+/A76/7<AC;@77/A76/@786Q//
O;<<=3>?@/a;2>C>R8E;3/
•  e>hC7/>3D;6<8E;3/;3/5;9?/
   /
•  O;=3?6@/67B>7F9/NcTb/#/?;/#&/A76/8:=C?/
   A;A=C8E;3Q/
   /
•  O;<<=3>?@/K78C?J/[;6G769/Nj/cTb/$/A76/
   8:=C?/A;A=C8E;3Q//

Más contenido relacionado

Destacado (8)

Brands gat
Brands gatBrands gat
Brands gat
 
Brands so(o net)
Brands so(o net)Brands so(o net)
Brands so(o net)
 
6 discussion-paper-investment-framework
6 discussion-paper-investment-framework6 discussion-paper-investment-framework
6 discussion-paper-investment-framework
 
konsep dan ruang lingkup beberapa faktor penyebab terjadinya perubahan sosial
konsep dan ruang lingkup beberapa faktor penyebab terjadinya perubahan sosialkonsep dan ruang lingkup beberapa faktor penyebab terjadinya perubahan sosial
konsep dan ruang lingkup beberapa faktor penyebab terjadinya perubahan sosial
 
Brands math
Brands mathBrands math
Brands math
 
Brands physics
Brands physicsBrands physics
Brands physics
 
Brands thai (o net)
Brands thai (o net)Brands thai (o net)
Brands thai (o net)
 
Brands chemistry
Brands chemistryBrands chemistry
Brands chemistry
 

Similar a Investment framwork tanzania_cs-powerpoint

Mobile Social Apps Market Eng version
Mobile Social Apps Market Eng versionMobile Social Apps Market Eng version
Mobile Social Apps Market Eng version01Booster
 
W Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking HinalW Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking Hinalkeletsor
 
W Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking HinalW Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking Hinalkeletsor
 
Radical Collaboration: Tools for Partnering with Community Members
Radical Collaboration: Tools for Partnering with Community MembersRadical Collaboration: Tools for Partnering with Community Members
Radical Collaboration: Tools for Partnering with Community MembersNina Simon
 
JaanSi Solutions & Services profile (v1.0)
JaanSi Solutions & Services profile (v1.0)JaanSi Solutions & Services profile (v1.0)
JaanSi Solutions & Services profile (v1.0)Siddhartha Shankar
 
Royal Ten Cate: Faster, cheaper and better than the market thinks
Royal Ten Cate: Faster, cheaper and better than the market thinksRoyal Ten Cate: Faster, cheaper and better than the market thinks
Royal Ten Cate: Faster, cheaper and better than the market thinksGert Steens
 
No deal road show 4 q04
No deal road show   4 q04No deal road show   4 q04
No deal road show 4 q04Braskem_RI
 
Cranfield Large Scale CO2 Injection, USA
Cranfield Large Scale CO2 Injection, USACranfield Large Scale CO2 Injection, USA
Cranfield Large Scale CO2 Injection, USAGlobal CCS Institute
 
Villa Alhambra Financials Sept. 2012
Villa Alhambra Financials Sept. 2012Villa Alhambra Financials Sept. 2012
Villa Alhambra Financials Sept. 2012VillaAlhambra
 
Biofuel For Transport in Sweden
Biofuel For Transport in SwedenBiofuel For Transport in Sweden
Biofuel For Transport in SwedenLenaDahlman
 
Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Kristofer Björkman
 
Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Alexander Mason
 

Similar a Investment framwork tanzania_cs-powerpoint (20)

Mucoliticos v2
Mucoliticos v2Mucoliticos v2
Mucoliticos v2
 
Mobile Social Apps Market Eng version
Mobile Social Apps Market Eng versionMobile Social Apps Market Eng version
Mobile Social Apps Market Eng version
 
W Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking HinalW Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking Hinal
 
W Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking HinalW Statement On Waterpipe Smoking Hinal
W Statement On Waterpipe Smoking Hinal
 
Radical Collaboration: Tools for Partnering with Community Members
Radical Collaboration: Tools for Partnering with Community MembersRadical Collaboration: Tools for Partnering with Community Members
Radical Collaboration: Tools for Partnering with Community Members
 
JaanSi Solutions & Services profile (v1.0)
JaanSi Solutions & Services profile (v1.0)JaanSi Solutions & Services profile (v1.0)
JaanSi Solutions & Services profile (v1.0)
 
03 opuscolo sicurezza cantieri - asle rlst
03   opuscolo sicurezza cantieri - asle rlst03   opuscolo sicurezza cantieri - asle rlst
03 opuscolo sicurezza cantieri - asle rlst
 
03 opuscolo sicurezza cantieri - asle rlst
03   opuscolo sicurezza cantieri - asle rlst03   opuscolo sicurezza cantieri - asle rlst
03 opuscolo sicurezza cantieri - asle rlst
 
Tribal Leadership with Dave Logan
Tribal Leadership with Dave LoganTribal Leadership with Dave Logan
Tribal Leadership with Dave Logan
 
Royal Ten Cate: Faster, cheaper and better than the market thinks
Royal Ten Cate: Faster, cheaper and better than the market thinksRoyal Ten Cate: Faster, cheaper and better than the market thinks
Royal Ten Cate: Faster, cheaper and better than the market thinks
 
No deal road show 4 q04
No deal road show   4 q04No deal road show   4 q04
No deal road show 4 q04
 
Cranfield Large Scale CO2 Injection, USA
Cranfield Large Scale CO2 Injection, USACranfield Large Scale CO2 Injection, USA
Cranfield Large Scale CO2 Injection, USA
 
Villa Alhambra Financials Sept. 2012
Villa Alhambra Financials Sept. 2012Villa Alhambra Financials Sept. 2012
Villa Alhambra Financials Sept. 2012
 
Biofuel For Transport in Sweden
Biofuel For Transport in SwedenBiofuel For Transport in Sweden
Biofuel For Transport in Sweden
 
Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010
 
Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010Cision Nordic Social Media Survey 2010
Cision Nordic Social Media Survey 2010
 
EB-85 A
EB-85 AEB-85 A
EB-85 A
 
Convocatoria de propuestas MCP 10ma Ronda
Convocatoria de propuestas MCP 10ma RondaConvocatoria de propuestas MCP 10ma Ronda
Convocatoria de propuestas MCP 10ma Ronda
 
Betagov content testing 13.1.2012 final
Betagov content testing 13.1.2012 finalBetagov content testing 13.1.2012 final
Betagov content testing 13.1.2012 final
 
Chi2 10b
Chi2 10bChi2 10b
Chi2 10b
 

Más de Indonesia AIDS Coalition

Más de Indonesia AIDS Coalition (13)

12 r11 css-info_note_en1
12 r11 css-info_note_en112 r11 css-info_note_en1
12 r11 css-info_note_en1
 
11 community systems-strengthening_framework-updated-nov-2011
11 community systems-strengthening_framework-updated-nov-201111 community systems-strengthening_framework-updated-nov-2011
11 community systems-strengthening_framework-updated-nov-2011
 
10 core global-fundstrategy_framework_en1
10 core global-fundstrategy_framework_en110 core global-fundstrategy_framework_en1
10 core global-fundstrategy_framework_en1
 
7 itpc-community-treatment-2.0-report
7 itpc-community-treatment-2.0-report7 itpc-community-treatment-2.0-report
7 itpc-community-treatment-2.0-report
 
5 community-mobilization-and-if-programmatic-areas-draft
5 community-mobilization-and-if-programmatic-areas-draft5 community-mobilization-and-if-programmatic-areas-draft
5 community-mobilization-and-if-programmatic-areas-draft
 
4 community-mobilization-and-the-if
4 community-mobilization-and-the-if4 community-mobilization-and-the-if
4 community-mobilization-and-the-if
 
3 investment-framework-summary-unaids-issues-brief
3 investment-framework-summary-unaids-issues-brief3 investment-framework-summary-unaids-issues-brief
3 investment-framework-summary-unaids-issues-brief
 
2 supplementary-webappendix-if-lancet-paper
2 supplementary-webappendix-if-lancet-paper2 supplementary-webappendix-if-lancet-paper
2 supplementary-webappendix-if-lancet-paper
 
13 tfm request-info_note_en1
13 tfm request-info_note_en113 tfm request-info_note_en1
13 tfm request-info_note_en1
 
Presentasi Sosialisasi People Health Movement (PHM)
Presentasi Sosialisasi People Health Movement (PHM)Presentasi Sosialisasi People Health Movement (PHM)
Presentasi Sosialisasi People Health Movement (PHM)
 
Presentasi Sosialisasi People Health Movement (PHM)
Presentasi Sosialisasi People Health Movement (PHM)Presentasi Sosialisasi People Health Movement (PHM)
Presentasi Sosialisasi People Health Movement (PHM)
 
Kesenjangan dan keadilan
Kesenjangan dan keadilanKesenjangan dan keadilan
Kesenjangan dan keadilan
 
Kesenjangan dan keadilan
Kesenjangan dan keadilanKesenjangan dan keadilan
Kesenjangan dan keadilan
 

Último

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 

Último (20)

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 

Investment framwork tanzania_cs-powerpoint

  • 1. !"#$%"&#'$()*$#)"+,-*$%.,/"0.,")1$"2$(3.#($")."!&45" " 6.,$"7-89$"0.,")1$"6.#$:"%;)1;#"-"+,-*$%.,/".0" 51-,$<"2$(3.#(;=;8;):"
  • 2. Resources available for HIV in low and middle income countries, 1986-2010
  • 3. We have done a lot… !  >#3,$?$<$#)$<"(?-8$"93".0"@&7" 3,$'$#A.#B"),$-)*$#)B"?-,$"-#<" (933.,)" !  4$?8;#$";#",-)$".0"#$%"@&7" ;#0$?A.#(";#"*-#:"?.9#),;$(" !  6.,$")1-#"CDC"*;88;.#"3$.38$".#" !2E" !  6;88;.#(".0".,31-#(",$?$;';#F"=-(;?" $<9?-A.#B"1$-8)1B"(.?;-8"3,.)$?A.#"
  • 4. But we can do better 5?-8$"93")."<-)$"F9;<$<"=:"-" G?.**.<;):"-33,.-?1H" " !  >#(:()$*-A?"3,;.,;A(-A.#"-#<" ;#'$()*$#)"%;)1"8;*;)$<"=-(;(";#" ?.9#),:"$3;<$*;.8.F:"-#<"?.#)$I)" !  2$(.9,?$("(3,$-<")1;#8:"-?,.((" *-#:"3-,-88$8";#)$,'$#A.#(" !  +.?9(".#"<;(?,$)$";#)$,'$#A.#(" ,-)1$,")1-#".'$,-88",$(98)("8$-<;#F" )."-"0,-F*$#)$<",$(3.#($"
  • 5. New Investment Framework CRITICAL BASIC PROGRAMME ACTIVITIES OBJECTIVES ENABLERS Social enablers Key Children & populations mothers •  Political commitment & Stopping new advocacy •  Laws, policies & infections practices •  Community mobilization Behaviour •  Stigma reduction change Condoms •  Mass media •  Local responses, to change risk environment Programme enablers Keeping •  Community-centered people alive design & delivery •  Programme communication Care & Male •  Management & incentives treatment circumcision •  Production & distribution •  Research & innovation SYNERGIES WITH DEVELOPMENT SECTORS Social protection; Education; Legal Reform; Gender equality; Poverty reduction; Gender-based violence; Health systems (incl. treatment of STIs, blood safety); Community systems; Employer practices.
  • 6. Three investment scenarios Impact on the epidemic %" %! $" >54"JK;88;.#(L" $! K9(;#$(("-("9(9-8" #" M"NDO" R$%"@&7"&#0$?A.#(" M"NDP" J*;88;.#(L" #! M"QDO" " M"QDP" M"PDO" ! M"P" $!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!
  • 7. Three investment scenarios Impact on the epidemic %" %! $" >54"JK;88;.#(L" $! &#'$()*$#)"0,-*$%.,/" K9(;#$(("-("9(9-8" #" M"NDO" R$%"@&7"&#0$?A.#(" M"NDP" J*;88;.#(L" #! M"QDO" " M"QDP" M"PDO" ! M"P" $!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!
  • 8. Three investment scenarios Impact on the epidemic %" 2-3;<"(?-8$"93" 3,$';.9("3,.S$?A.#(" %! $" >54"JK;88;.#(L" $! &#'$()*$#)"0,-*$%.,/" K9(;#$(("-("9(9-8" #" M"NDO" R$%"@&7"&#0$?A.#(" M"NDP" J*;88;.#(L" #! M"QDO" " M"QDP" M"PDO" ! M"P" $!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!
  • 9. E1$"#$%";#'$()*$#)"0,-*$%.,/" +.?9(".#"%1-)"*-/$("-"<;T$,$#?$" >54"JK;88;.#(L" $" $! 5:#$,F;$(" #" V,;A?-8"W#-=8$,(" #! " K-(;?"U,.F,-**$" !?A';A$(" ! $!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!
  • 10. ART coverage in 2015 by CD4 count #!!" CD4 350 +!" *!" 15 million )!" (!" V.'$,-F$ '!" &!" %!" T4P 13.1 million (health) $!" #!" !" ,'!! %'!-&++ $'!-%&+ $!!-$&+ #!!-#++ '!-++ .'! V4X"V.9#)"J?$88(Y*8L
  • 11. Returns on investment of new investment framework (2011-2020) Outcomes Total infections averted More than 12 million Infant infections averted 1.9 million Deaths averted 7.4 million Life years gained 29.4 million
  • 12. New investment framework: the tipping point R$%8:"$8;F;=8$"0.,"),$-)*$#)" R$%8:";#0$?)$<"
  • 13. New infections, behaviour change and treatment coverage in Botswana Behaviour change New infections and treatment coverage
  • 14. Cost and economic returns 2011 to 2020 Cost/Returns Total additional investment US$46.5 Billion (over 10 years) Future treatment need US$40 Billion averted US$1,060 Life years gained per life year gained
  • 15. Investment framework projections for new HIV infections Optimized investment will lead to rapid declines in new HIV infections in many countries
  • 16. V.**9#;):"*.=;8;Z-A.#"-((9*3A.#(";#")1$" ;#'$()*$#)"0,-*$%.,/"" V.()"$#'$8.3$["?.**9#;):"*.=;8;(-A.#"?.*3.#$#)".0")1$" ?,;A?-8"$#-=8$,(""" " ////$!##//0!1%23/ //$!#'/0!1(/23/ / /$!$!/0#1!/23// / !((9*3A.#([" •  43567897:/5;<<=3>?@/58A85>?@// •  >3567897:/5;<<=3>?@/976B>57/:7C>B76@/// •  377:/D;6/67<=3768E;3/;D/5;<<=3>?@/83:/C8@/F;6G769// •  377:/D;6/?68>3>3HI/H=>:8357I/9=A76B>9>;3/ •  A86E5>A8E;3/;D/A7;AC7/C>B>3H/F>?J/K4L/
  • 17. V.**9#;):"*.=;8;Z-A.#["*-/$("(?-8$"93"3.((;=8$"" •  R9*=$,".0"3$.38$")$()$<")1,.9F1"?.**9#;):" *.=;8;Z-A.#"" /$!#!M/&(/<>CC>;3/NLOPQ/// /$!#'M/#!+/<>CC>;3// / •  5$,';?$"<$8;'$,:"?.()("J),$-)*$#)L"" /$!#!M/0#)+/A76/@786/// /$!$!M/0#$'/A76/@786/N0#)/>3/C;F/>35;<7/5;=3?6>79Q// / •  4,;';#F"?.()("<.%#["0$%$,".9)3-A$#)"';(;)(B" ?.**9#;):"(933.,)"($,';?$"*.<-8;A$(" •  K$$,"@$-8)1"]9)?.*$("
  • 18. V.**9#;):"*.=;8;Z-A.#["" ;#?,$-($("$T$?A'$#$((" •  O;<<=3>?@/<;2>C>98E;3/>3567897:/K4L/?79E3H/68?79/D;=6- D;C:/>3/P83R83>8I/S><282F7I/T;=?J/UD6>58/83:/PJ8>C83:1/ // •  O;39>9?73?/5;3:;</=97/>3/A89?/#$/<;3?J9/&/E<79/J>HJ76/>3/ 5;<<=3>E79/F>?J/H;;:/5;<<=3>?@/73H8H7<73?/NV73@8Q// // •  K@A;?J7E58C/5>65=<5>9>;3/<;:7C/VF8S=C=-W8?8C/M// –  5;67/>3?76B73E;3M//$&!I!!!/>3D75E;39/8B76?7:/;B76/?73/@7869/ –  F>?J/7382C769M/&$!I!!!/>3D75E;39/8B76?7:I/F>?J/<;:79?/ <86H>38C/>3567897/>3/5;9?9/ /
  • 20. E-#Z-#;-["-##9-8"#$%"@&7";#0$?A.#(B"NPQQMNPNP" #(!!!!/ #&!!!!/ K-($8;#$"J=9(;#$(("-("9(9-8L" #$!!!!/ #!!!!!/ *!!!!/ (!!!!/ &#'$()*$#)"+,-*$%.,/" &!!!!/ $!!!!/ !/ $!##/ $!#$/ $!#%/ $!#&/ $!#'/ $!#(/ $!#)/ $!#*/ $!#+/ $!$!/
  • 21. E-#Z-#;-["-##9-8"!&45"<$-)1(B"NPQQMNPNP" #&!!!!/ K-($8;#$"J=9(;#$(("-("9(9-8L" #$!!!!/ #!!!!!/ *!!!!/ (!!!!/ &!!!!/ &#'$()*$#)"+,-*$%.,/" $!!!!/ !/ $!##/$!#$/$!#%/$!#&/$!#'/$!#(/$!#)/$!#*/$!#+/$!$!/
  • 24. Resources available for HIV in low and middle income countries, globally, 2002-2010
  • 25. Percentage of care and treatment expenditure from international sources
  • 26. Few donors meet the development assistance targets Norway 1.10% Luxembourg 1.09% Sweden 0.97% Denmark 0.90% Netherlands 0.81% Belgium 0.64% United Kingdom 0.56% Finland 0.55% Ireland 0.53% France 0.50% Spain 0.43% Switzerland 0.41% Net development assistance Germany 0.38% Canada 0.33% in 2001 as % of gross Austria Australia 0.32% 0.32% national income Portugal 0.29% New Zealand 0.26% United States 0.21% Japan 0.20% Greece 0.17% Italy 0.15% Korea 0.12% 0% 0.3% 0.5% 0.7% 1% 1.2%
  • 27. Measuring national commitment to AIDS: the Domestic Investment Priority Index SOURCE: UNAIDS expenditure data; WHO data on the burden disease; and economic data from the International Monetary Fund World Economic Outlook database
  • 28. Economic growth in Africa, 1970–2010 Third-fastest growing region in the World
  • 29. Three options for increasing domestic public HIV investment in Africa
  • 30. Projected resource needs (in USD billion) Assumed increases of domestic contributions by BRICS and others within ability to pay (economic growth and towards Abudja targets) Development Assistance 8.0 10.7 9.4 12.7 11.8 13.6 13.5 13.0 11.9 11.3 Domestic financing 9.7 LI LMI UMI XY4OT/
  • 31. T;<7/Z=79E;39 / •  [J8?/867/?J7/9?68?7H>5/;A73>3H9/D;6/8/37F/ :>8C;H=7/86;=3:/75>735@]/ •  U67/?J767/;2B>;=9/<>9-<8?5J79/27?F773/?J7/ 7A>:7<>5/83:/?J7/679A;397]/ •  [J>5J/867/?J7/D85?;69/?J8?/<8G7/>?/:>5=C?/?;/ 958C7/=A/289>5/A6;H68<<7/5;<A;373?9]// •  K;F/5;=C:/A86?3769/J7CA/>3/8AAC>58E;3/;D/?J7/ 4^/8AA6;85J/
  • 32. The beginning of the end of AIDS is in our hands
  • 34. Y785J>3H/A7;AC7/F>?J/976B>579M / _`8<AC79/D;6/$!#'/ V.'$,-F$" J3.398-A.#",$-?1$<L " O;3:;<9/N:>95;6:83?/5;=AC79Q/ (!" / O;3:;<9/NJ>HJ/6>9G/A;AQ/ '!" / T7`/F;6G/ (!" / aTa/A6;H68<<79/ (!" / 4bc/A6;H68<<79/ (!" / 6;88;.#" K4L/?79E3H/ %$! / UYP/NOb&/%'!I/P&dQ/ ?;F86:9/#' /
  • 35. O;9?/A76/A8E73?/A76/@786/ / NF7>HJ?7:/8B768H7/>3/cT0Q / " " " " "NPQP " "NPQO " "NPNP" / e82/N37F/A8E73?9Q/////// /#*!//// / /#$+/ / /)+// / e82/N5;3?/A8E73?9Q//////// /#*!/ / /#$*/ / /)(// / T76B>57/:7C>B76@/ / /#)(/ / /#&&/ / /##$// / #9?/e>37/UYL9/ / / /#'' / /#&)/ / /')// / $3:/e>37/UYL9/ / / /#()* / /+*& / /$+'//
  • 36. P79E3H/83:/O;=397C>3H / O;B768H7/83:/5;9?/A76/A769;3/ !"#$%&'(%)*+',$%)"-,#'**'.%/,.%$'#$'. 0:1 091 081 071 061 051 041 031 021 01 1; 6; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 26 36 46 56 66 76 86 96 :6 12 14 16 31 51 86 1< 1< 1< 1< 1< 1< !"='(/>'
  • 37. fTP/O;9?/U99=<AE;39 / V.()".0"6$)1-<.#$["" •  %%5/D;6/*!<H/>3/4683/?;/0$1!(/D;6/*!<H/>3/ 43:;379>8/ •  U2;=?/cTb/#!!!/A76/A769;3/@786/ •  g;>3H/:;F3/2@/$!"/>3/$!#'/83:/2@/J8CD/>3/ $!$!/
  • 38. X7J8B>;6/OJ83H7/d6;H68<<79 / •  e>hC7/7B>:7357/D;6/7i75EB73799/ •  e>hC7/>3D;6<8E;3/;3/5;9?/ •  U9/8/A6;`@M/5;9?/F;6GAC857/A6;H68<9/N2@/$!#'I/ '!"/5;B768H7/;D/?J7/#&*/<>CC>;3/7<AC;@779/>3/ ?J7/D;6<8C/975?;6/>3/5;=3?6>79/F>?J/ H73768C>R7:/7A>:7<>59I/8B768H7/=3>?/5;9?/;D/cT 0/+/A76/7<AC;@77/A76/@786Q//
  • 39. O;<<=3>?@/a;2>C>R8E;3/ •  e>hC7/>3D;6<8E;3/;3/5;9?/ / •  O;=3?6@/67B>7F9/NcTb/#/?;/#&/A76/8:=C?/ A;A=C8E;3Q/ / •  O;<<=3>?@/K78C?J/[;6G769/Nj/cTb/$/A76/ 8:=C?/A;A=C8E;3Q//